Plain-English translation of NCT05493267 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether adding an immune-boosting therapy to standard antibiotic treatment can help people with multidrug-resistant tuberculosis (TB that doesn't respond to common antibiotics). The new approach uses two medications—zoledronic acid and interleukin 2—to activate specific immune cells in your body that are particularly good at fighting tuberculosis bacteria that hide inside your cells. The goal is to help your body's own immune system kill the bacteria that antibiotics alone may not be able to reach.
Drug-resistant tuberculosis is becoming harder to treat, and even with the best antibiotic combinations available, fewer than half of patients are cured. Researchers believe that by boosting your immune system to fight the infection directly, this medication could give antibiotic treatment a better chance of working, especially for people whose current treatments aren't helping.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the standard antibiotic treatment for drug-resistant TB that your doctors recommend, plus the new immune-boosting medications (zoledronic acid and interleukin 2) given as injections. You will have regular visits with the research team to monitor how well the treatment is working, check for any side effects, and have blood tests to see how your immune cells are responding. The trial is enrolling 30 people total at Shanghai Pulmonary Hospital in China.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Post-approval monitoring
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Collaborators
Shanghai Public Health Clinical Center, Huashan Hospital
Enrollment target
~30 participants
Started
August 2022
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in August 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sha Wei
Shanghai Pulmonary Hospital, Shanghai, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.